Cancer treatment usually involves surgery in addition to radiation and chemotherapy. The chemotherapeutic agents that are being used are often not very effective and are toxic to both malignant and normal cells. Therefore, this study was conducted in order to find potential, chemotherapeutic agents that would be effective toward malignant cells but have minimal effects on normal cells. One of the candidates tested was a modified form of tryptamine, ICX-550. The rationale is that since tryptamine is a natural substance that is found in plants and animals and has, in the past, shown some anticancer activity, its use as a chemotherapeutic agent would yield minimal effects in humans. Therefore, the ability of ICX-550 to induce cell death was tested in normal (OK) and malignant (Daudi, SKMG) cells. Our results showed that acute treatment (1&10 mM; 24 hrs) of ICX-550 induced cell death in Daudi and SKMG cells, but not in OK cells. Chronic treatment with a lower dose of ICX-550 (100 nM; 7 day) induced apoptosis in Daudi and SKMG, but not in OK cells. Finally, chronic treatment with even lower doses of ICX-550 inhibits proliferation of malignant, but not normal cells. Therefore, ICX-550 is an excellent candidate as a chemotherapeutic agent that would be effective against malignant cells but has minimal effect on normal cells.